Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A1MMCC8
Tue, 11.11.2025
Medios AG
Press releaseMedios AG achieves strong growth in earnings and profit margin in the first nine months of 2025
Revenue increases by 9.2% to €1,530.0 million
Disproportionately high EBITDA pre1 increase of 26.1%
Organic EBITDA pre1 growth of 5.1%
Cash flow from operating activities almost doubles
Significant improvement in earnings per share to € [ … ]
Mon, 03.11.2025
Medios AG
Press release
Thomas Meier becomes new CEO of Medios AG
Berlin, November 3, 2025 – The Supervisory Board of Medios AG has appointed Thomas Meier as a member of the Executive Board with effect from February 1, 2026, and designated him the new Chief Executive Officer (CEO) of the Company. He succeeds Matthias Gaertner, who will remain in office un [ … ]
Fri, 24.10.2025
Medios AG
Press release
Medios AG: Block placement of Bencis shares
Berlin, October 24, 2025 – The Medios-Group (“Medios“ or “the Company”), a leading provider of Specialty Pharma in Europe, was informed that Bencis Capital Partners B.V. ("Bencis") has reallocated its entire shareholding in Medios AG. The shares, which represent a total of approx. 6.7% of [ … ]
Wed, 13.08.2025
Medios AG
Press release
Medios accelerates growth in the first half of 2025 and significantly increases earnings
Revenue up 9.3% to €991.7 million
EBITDA pre1 up by a disproportionate 48.8%
Organic EBITDA pre1 growth of 12.3%
Earnings per share almost doubled to €0.50
Successful public share buyback offer
Outlook for 2025 confirmed: Further increase i [ … ]
Fri, 11.07.2025
Medios AG
NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTE AT THE END OF THIS PRESS RELEASE.
Press release
Medios successfully c [ … ]
Tue, 27.05.2025
Medios AG
Press release
Medios AG Annual General Meeting 2025: Shareholders approve all proposed resolutions
Berlin, May 27, 2025 – The shareholders of Medios, a leading provider of Specialty Pharma in Europe, today approved all resolutions proposed by the Executive Board and Supervisory Board at the 2025 Annual General Meeting with a large majority. In to [ … ]
Tue, 13.05.2025
Medios AG
Press release
Medios starts 2025 financial year successfully with significant increase in earnings
Revenue up 6.2% to €484.7 million in the first quarter
Significantly higher increase in EBITDA pre1 of 52.9% to €23.1 million with margin improvement to 4.8%
Earnings per share increased to €0.25 from €0.17 in Q1 2024
2025 forecast confirmed: Fur [ … ]
Mon, 12.05.2025
Medios AG
Press release
Medios repositions itself for the next phase of its corporate development
The company's founding team is leaving Medios at its own request
Matthias Gärtner hands over the CEO position to a successor after a transition period
Mi-Young Miehler (COO) will leave the company on 30 June 2025
Berlin, May 12, 2025 - Medios AG ("Medios"), [ … ]
Tue, 25.03.2025
Medios AG
Press release
Medios expects further growth in revenue and earnings after record year 2024
Consolidated revenue increases to €1.9 billion (+5.5%)
EBITDA pre1 with disproportionate growth of 30.5% and significantly improved EBITDA pre1 margin of 4.2% (previous year: 3.4%)
Strong operating cash flow
Outlook for 2025: revenue growth to around €2. [ … ]
Tue, 04.03.2025
Medios AG
Press release
Preliminary figures for Medios AG 2024: Significant increase in earnings and margins – positive outlook for 2025
Preliminary figures 2024
Revenue increases to around €1.9 billion (+5.5%)
Disproportionate increase of EBITDA pre1 to around €79 million (+31%); EBITDA pre1 margin significantly improved to around 4.2% (previous year: 3.4 [ … ]
